Drug
Glecaprevir and pibrentasvir clinical trials
Also written ABT-493 and ABT-530.
- studies test it
- 46
- open now
- 3
- in phase 3
- 27
- first study started
- 2014
Keep track of what changes. Save the glecaprevir and pibrentasvir studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
46 studies that test it; most in 2017 (9)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 7 |
| 2016 | 7 |
| 2017 | 9 |
| 2018 | 4 |
| 2019 | 5 |
| 2020 | 4 |
| 2021 | 4 |
| 2022 | 2 |
| 2023 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 3
- Phase 2
- 11
- Phase 3
- 27
- Phase 4
- 11
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 22 · Other 24
AbbVie (22) · Kirby Institute (4) · Massachusetts General Hospital (4) · White River Junction Veterans Affairs Medical Center (2) · NYU Langone Health (2) · Johns Hopkins University (2) · Mayo Clinic (1) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (1)
Often tested with
Tested in the same studies.
Ribavirin (4) · Sofosbuvir (2) · Glecaprevir (2) · Pibrentasvir (2) · Sofosbuvir-velpatasvir drug combination (1) · Elbasvir-grazoprevir drug combination (1) · Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (1) · Velpatasvir (1)
Studies
Open first, then newest update. How each study uses glecaprevir and pibrentasvir is read from its arms, and is right about nine times in ten.
Testing it · 46
- Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIVRecruitingPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT07040319Written as Glecaprevir/pibrentasvir
- Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvirRecruitingPhase 4Kirby InstituteNCT03855917Written as Glecaprevir/pibrentasvir (300mg/120mg)
- Glecaprevir/Pibrentasvir for Post-traumatic Stress DisorderRecruitingPhase 2/3White River Junction Veterans Affairs Medical CenterNCT05637879Written as Glecaprevir/pibrentasvir
- A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant RecipientsActive, not recruitingPhase 4Mayo ClinicNCT04508907Written as Mavyret
- Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)CompletedPhase 3AbbVieNCT04903626Written as Glecaprevir/Pibrentasvir (GLE/PIB)
- QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/PibrentasvirTerminatedPhase 4Massachusetts General HospitalNCT04515797Written as Glecaprevir and Pibrentasvir
- Glecaprevir/Pibrentasvir for the Treatment of PTSDCompletedPhase 2/3White River Junction Veterans Affairs Medical CenterNCT05446857Written as Glecaprevir / Pibrentasvir Pill
- Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus InfectionCompletedPhase 2Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsNCT04042740Written as Glecaprevir/Pibrentasvir (G/P)
- A Single-center Pilot Study Evaluating a Preemptive Short Course of Glecaprevir/Pibrentasvir in Hepatitis C Positive to Negative Kidney TransplantationCompletedEarly Phase 1NYU Langone HealthNCT04682509Written as Glecaprevir/pibrentasvir
- Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic DonorsCompletedPhase 4Johns Hopkins UniversityNCT04575896Written as Glecaprevir/pibrentasvir
- Utilization of Hepatitis C Positive Kidneys in Negative RecipientsCompletedPhase 2/3Ohio State UniversityNCT03801707Written as Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET]
- Transplanting Hepatitis C Kidneys Into Negative Kidney RecipientsCompletedPhase 1/2University of PennsylvaniaNCT02743897Written as Mavyret
- A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) InfectionCompletedPhase 2/3AbbVieNCT03067129Written as Glecaprevir/Pibrentasvir Adult Formulation
- Providing PrEP, Hepatitis C Treatment, and MOUD Through Telemedicine at Greensboro SSPCompletedNot applicableDuke UniversityNCT05108935Written as Mavyret
- Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung TransplantTerminatedPhase 4Massachusetts General HospitalNCT03625687Written as Clinically prescribed direct acting antiviral (Mavyret or Epclusa) HCV treatment for 8 weeks
- A TEst and Treat Intervention aMong Current People Who Inject Drugs With HCV Attending Needle and Syringe PrOgramsCompletedNot applicableKirby InstituteNCT03492112Written as Glecaprevir/pibrentasvir
- Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/PCompletedPhase 3Kirby InstituteNCT02634008Written as Glecaprevir/pibrentasvir
- Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ DonorCompletedPhase 1/2University of California, San DiegoNCT04596475Written as glecaprevir/pibrentasvir (GLE/PIB)
- Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical StudyCompletedPhase 3AbbVieNCT02939989Written as Glecaprevir/Pibrentasvir
- Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis AccessWithdrawnPhase 4Massachusetts General HospitalNCT04614142Written as Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]
See all 46 studies that test glecaprevir and pibrentasvir →
Given in every arm · 3 — glecaprevir and pibrentasvir is usual care beside what is tested
- Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject DrugsTerminatedNot applicableKirby InstituteNCT03981211Written as Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet
- HCV Test and Treat Utilizing Simplified HCV Patient EducationTerminatedPhase 4Weill Medical College of Cornell UniversityNCT05582681Written as Glecaprevir and Pibrentasvir
- Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV SubjectsCompletedPhase 3University of FloridaNCT03092375Written as Glecaprevir/Pibrentasvir (G/P) 300mg/120mg